RedHill Wins Two More U.S. Patents on Gastrointestinal Therapy BEKINDA

RedHill Wins Two More U.S. Patents on Gastrointestinal Therapy BEKINDA
RedHill Biopharma has received two more U.S. patents for its gastrointestinal therapy BEKINDA (ondansetron). The patents cover RedHill's propriety formulation of its extended-release ondansetron tablet, and the way BEKINDA is used in treatment. "We are very pleased with the allowance of two additional U.S. patents for BEKINDA," Danielle Abramson, RedHill's director of intellectual property and research, said in a press release. "This is an important addition to RedHill's strong IP [intellectual property] portfolio that will further enhance our protection of BEKINDA. "We are approaching significant milestones with BEKINDA in the coming months," Abramson added. She was referring to the results of two ongoing clinical trials that are expected in the second and third quarters of 2017. BEKINDA is an anti-emetic drug, or one that treats nausea and vomiting. It targets multiple gastrointestinal problems, including irritable bowel syndrome (IBS), acute gastroenteritis and gastritis. Patients take the tablet once a day. The randomized, double-blind, placebo-controlled Phase 3 GUARD clinical trial of 24 mg of BEKINDA (NCT02246439) is continuing. It is evaluating its effectiveness and safety as a treatment for vomiting resulting from acute gastroenteritis or gastritis. RedHill announced in February that the last of the 320 adults and children in the GUARD study had completed the treatment and observation period. Key results of the trial, which took part at 29 U.S. sites, are expected in the second quarter of 2017. Also under way is a randomized, double-blind, placebo-controlled Phase 2 trial (NCT02757105). It is evaluating the effectiveness and safety of the 12-mg bimodal-release tablet form of BEKINDA for treating adults with IBS-related diarrhea, or IBS-D
Subscribe or to access all post and page content.